$\require{mediawiki-texvc}$
  • 검색어에 아래의 연산자를 사용하시면 더 정확한 검색결과를 얻을 수 있습니다.
  • 검색연산자
검색연산자 기능 검색시 예
() 우선순위가 가장 높은 연산자 예1) (나노 (기계 | machine))
공백 두 개의 검색어(식)을 모두 포함하고 있는 문서 검색 예1) (나노 기계)
예2) 나노 장영실
| 두 개의 검색어(식) 중 하나 이상 포함하고 있는 문서 검색 예1) (줄기세포 | 면역)
예2) 줄기세포 | 장영실
! NOT 이후에 있는 검색어가 포함된 문서는 제외 예1) (황금 !백금)
예2) !image
* 검색어의 *란에 0개 이상의 임의의 문자가 포함된 문서 검색 예) semi*
"" 따옴표 내의 구문과 완전히 일치하는 문서만 검색 예) "Transform and Quantization"
쳇봇 이모티콘
안녕하세요!
ScienceON 챗봇입니다.
궁금한 것은 저에게 물어봐주세요.

논문 상세정보

Transdermal Delivery of Estradiol and Norethindrone Acetate: Effect of Vehicles and Pressure Sensitive Adhesive Matrix

Abstract

Addition of 30% propylene glycol was required to maintain sink condition in the evaluation of percutaneous absorption of estradiol and norethindrone acetate. The permeability of estradiol was higher in silicone and SIS adhesives. However, estradiol was crystallized in silicone, SIS, and SBS adhesive matrix. The permeability ratio of estradiol or norethindrone acetate from acrylic pressure sensitive adhesives varied widely depending on the functional group of the acrylic adhesives. PEO grafting to acrylic adhesive seemed to change physicochemical property of acrylic adhesive and increased the permeability of estradiol and norethindrone acetate significantly. On the contrary, highly cross-linked enhancer compatible acrylic adhesive decreased the permeability of both estradiol and norethindrone acetate. $Span^{\circledR}$ 20 provided the highest enhancing effect on the permeability of both estradiol and norethindrone acetate followed by oleic acid and $Crovol^{\circledR}$ EP40. The permeability of the drugs from the developed system was comparable to that from commercial $Combitran^{\circledR}$, although significantly lower amount of estradiol and norethindrone acetate were loaded in the developed system.

참고문헌 (19)

  1. E. Grodstein, M.J. Stampfer, J.E. Manson, G.A. Colditz, W.C. Willett, B. Rosner, EE. Speizer and C.H. Hennekens, Postmenopausal estrogen and progestin use and the risk of cardiovascular disease, N. Engl. J. Med. 335, 453-461 (1996) 
  2. C. Castelo-Branco, M.J. Martinez de Osaba, F. Pons and J. Gonzalez-Merlo, The effect of hormone replacement therapy on postmenopausal bone loss, Eur. J. Obstetr. Gynecol. Reprod. Biol. 44, 131-136 (1992) 
  3. E. Barrett-Connor and D. Gray, Hormone replacement therapy, heart disease, and other considerations, Annu. Rev. Public health, 19, 55-72 (1998) 
  4. H.K. Genant, J. Lucas, S. Weiss, M. Akin, R. Enkey, H. Mcnaney-Flint, R. Downs, J. Mortola, N. Watts, H.M. Yang, N. Banar, J.J. Brennan and J.C. Nolan, Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study, Arch. Intern. Med. 157, 2609-2615 (1997) 
  5. T. Holst and B. Salbach, Efficacy of a new 7 -day transdermal sequential estradiol/levonorgestrel patch in women, Maturitas, 41, 231-242 (2002) 
  6. R. Rossi, G. Origliani and M.G Modena, Transdermal 17-betaestradiol and risk of developing type 2 diabetes in a population of healthy, nonobese postmenopausal women, Diabetes Care. 27, 645-649 (2004) 
  7. E. Weiderpass, H.O. Adami, J.A. Baron, C. Magnusson, R. Bergstrom, A. Lindgren, N. Correia and J. Persson, Risk of endometrial cancer following estrogen replacement with and without progestins, J. Natl. Cancer Inst. 91, 1131-1137 (1999) 
  8. M. Hori, et al., Classification of percutaneous penetration enhancers. In: R.L. Bronaugh, H.I. Maibach Editors, Percutaneous Absorption: Mechanisms, Methodology, Drug Delivery, Marcel Dekker, New York, USA, pp. 197-211 (1989) 
  9. J.-H. Kim, C.H. Lee and H.-K. Choi, Transdennal delivery of physostigmine: Effects of enhancers and pressure sensitive adhesives, Drug Dev. Ind. Pharm., 28, 833-839 (2002) 
  10. T. Kokubo, K. Sugibayashi and Y. Morimoto, Interaction between drugs and pressure-sensitive adhesive in transdermal therapeutic systems, Pharm. Res. 11, 104-107 (1994) 
  11. J.-H. Kim, Y.-J. Cho and H.-K. Choi, Effect of vehicles and pressure sensitive adhesives in the permeation for tacrine across hairless mouse skin, Int. J. Pharm. 196, 105-113 (2000) 
  12. H.-K. Choi and J.T. Angello, Mathematical analysis and optimization of flow-through diffusion cell system. Pharm. Res. 11, 595-599 (1994) 
  13. X. Ma, J. Taw and C.M. Chiang, Control of drug crystallization in transdermal matrix system, Int. J. Pharm. 142, 115-119 (1996) 
  14. D.R. Friend and P. Catz, Effect of cosolvents on ethyl acetate enhanced percutaneous absorption of levonorgestrel, J. Control. Release, 12, 171-180 (1990) 
  15. G.S. Chen, D.O. Kim and Y.W. Chien, Dual-controlled transdermal delivery of levonorgestrel and estradiol: enhanced permeation and modulated delivery, J. Control. Release, 34, 129-143 (1995) 
  16. C. Grant, A. Gray, R. Paoletti, et al., Hormone replacement therapy, The Lancet, 354, 152-155 (1999) 
  17. M.J. Stampfer, G.A. Colditz, W.C. Willett, J.E. Manson, B. Rosner, E.E. Speizer and C.H. Hennekens, Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study, N Engl. J. Med. 325, 756-762 (1991) 
  18. M.S. Post, M.J. van der Moorenvan, W.M. Baal, M.A. Blankenstein, H.M. Merkus, M.Y. Kroeks, H.R. Franke, P. Kenemans and CD. Stehouwer, Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: A randomized placebo-controlled study, Am. J. Obstet. Gynecoz. 189, 1221-1227 (2003) 
  19. L.K. Pershing, G.E. Parry and L.D. Lambert, Disparity of in vitro and in vivo oleic acid-enhanced ${\beta}$-estradiol percutaneous absorption across human skin, Pharm. Res. 10, 1745-1750 (1993) 

이 논문을 인용한 문헌 (1)

  1. 2010. "" Archives of pharmacal research : a publication of the Pharmaceutical Society of Korea, 33(3): 339~351 

원문보기

원문 PDF 다운로드

  • ScienceON :

원문 URL 링크

원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다. (원문복사서비스 안내 바로 가기)

상세조회 0건 원문조회 0건

DOI 인용 스타일